Source comparison
CJC-1295 no DAC & Ipamorelin Synergistic GH Release: Protocol Comparison
Peak GH Amplitude (ng/mL) 8–12× baseline 5–8× baseline 12–18× baseline Synergistic protocol produces 40–50% higher peak GH than either peptide alone due to dual-pathway stimulation GH Pulse Duration (minutes) 90–120 60–90 150–180 Extended pulse from somatostat
This comparison does not assign a generated winner or score.
- Peak GH Amplitude (ng/mL)
- 8–12× baseline
- 5–8× baseline
- 12–18× baseline
- Synergistic protocol produces 40–50% higher peak GH than either peptide alone due to dual-pathway stimulation
- GH Pulse Duration (minutes)
- 90–120
- 60–90
- 150–180
- Extended pulse from somatostatin suppression allows greater IGF-1 induction per injection cycle
- IGF-1 Steady-State Elevation (% above baseline)
- +25–40%
- +15–25%
- +50–80%
- Higher sustained IGF-1 is the primary driver of tissue-level outcomes. Synergistic protocol delivers 2× the IGF-1 response
- Fat Loss Timeline (weeks to significance)
- 10–14
- 12–16
- 8–12
- Earlier onset due to amplified lipolytic signaling; visceral fat responds faster than subcutaneous
- Lean Mass Accretion (kg at week 16)
- 0.8–1.5
- 0.5–1.0
- 1.5–3.5
- Synergy produces additive nitrogen retention; not exponential but clinically meaningful compared to monotherapy
- Injection Frequency (optimal)
- 1–2× daily
- 2–3× daily
- CJC-1295's longer half-life allows less frequent dosing when combined; Ipamorelin compensates for shorter GHRH analog duration